Lawsuit alleges Inovio insiders misled shareholders on device manufacturing and FDA approval prospects

Kuehn Law is investigating whether Inovio Pharmaceuticals' officers and directors misled shareholders by hiding manufacturing issues with the CELLECTRA device and overstating the chances of FDA approval for the INO-3107 drug. The lawsuit claims Inovio failed to disclose delays and insufficient data for accelerated FDA review, potentially harming investors who bought shares before October 10, 2023. Shareholders are urged to contact the law firm to protect their rights as the case progresses.